CN110944650B - 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 - Google Patents

用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 Download PDF

Info

Publication number
CN110944650B
CN110944650B CN201880034095.5A CN201880034095A CN110944650B CN 110944650 B CN110944650 B CN 110944650B CN 201880034095 A CN201880034095 A CN 201880034095A CN 110944650 B CN110944650 B CN 110944650B
Authority
CN
China
Prior art keywords
chelator
composition
subject
metabolite
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880034095.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110944650A (zh
Inventor
安托尼·斯图尔特·坎贝尔
戴维·H·多纳伯迪昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapy Co
Axial Therapeutics Inc
Original Assignee
Axial Therapy Co
Axial Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapy Co, Axial Biotherapeutics Inc filed Critical Axial Therapy Co
Priority to CN202210138407.5A priority Critical patent/CN114569633B/zh
Publication of CN110944650A publication Critical patent/CN110944650A/zh
Application granted granted Critical
Publication of CN110944650B publication Critical patent/CN110944650B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880034095.5A 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 Expired - Fee Related CN110944650B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210138407.5A CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210138407.5A Division CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Publications (2)

Publication Number Publication Date
CN110944650A CN110944650A (zh) 2020-03-31
CN110944650B true CN110944650B (zh) 2022-03-04

Family

ID=63677186

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880034095.5A Expired - Fee Related CN110944650B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
CN202210138407.5A Expired - Fee Related CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210138407.5A Expired - Fee Related CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Country Status (9)

Country Link
US (4) US10617718B2 (enExample)
EP (1) EP3600349A4 (enExample)
JP (1) JP6978122B2 (enExample)
KR (1) KR102328323B1 (enExample)
CN (2) CN110944650B (enExample)
AU (3) AU2018243836B9 (enExample)
BR (1) BR112019020289A2 (enExample)
CA (2) CA3191747A1 (enExample)
WO (1) WO2018183986A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
JP7607659B2 (ja) * 2019-12-19 2024-12-27 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド トマトの搾りかすを用いたイヌの上昇した４－エチルフェニル硫酸と関連付けられた状態の治療およびリスクを低減する組成物および方法ならびにそのような状態のリスクにあるイヌを特定する方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029715A1 (en) * 1979-11-22 1981-06-03 Kureha Kagaku Kogyo Kabushiki Kaisha Porous spherical carbonaceous product and production thereof
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
CN103491949A (zh) * 2011-03-04 2014-01-01 株式会社吴羽 片剂型的口服给药用组合物及其制造方法
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
CN114949001A (zh) * 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
EP0029715A1 (en) * 1979-11-22 1981-06-03 Kureha Kagaku Kogyo Kabushiki Kaisha Porous spherical carbonaceous product and production thereof
CN103491949A (zh) * 2011-03-04 2014-01-01 株式会社吴羽 片剂型的口服给药用组合物及其制造方法
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract

Also Published As

Publication number Publication date
CN114569633A (zh) 2022-06-03
US11007219B2 (en) 2021-05-18
NZ758692A (en) 2022-03-25
BR112019020289A2 (pt) 2020-09-01
AU2018243836B2 (en) 2021-04-22
EP3600349A4 (en) 2020-09-30
CA3095724A1 (en) 2018-10-04
AU2021206871B2 (en) 2021-10-14
CA3191747A1 (en) 2018-10-04
AU2018243836B9 (en) 2021-05-13
AU2022200220A1 (en) 2022-02-10
US20230364135A1 (en) 2023-11-16
US20180303876A1 (en) 2018-10-25
JP6978122B2 (ja) 2021-12-08
KR102328323B1 (ko) 2021-11-19
JP2020513032A (ja) 2020-04-30
KR20200024133A (ko) 2020-03-06
AU2021206871A1 (en) 2021-08-12
CA3095724C (en) 2023-04-18
WO2018183986A1 (en) 2018-10-04
CN110944650A (zh) 2020-03-31
AU2018243836A1 (en) 2019-11-21
US10617718B2 (en) 2020-04-14
CN114569633B (zh) 2023-11-17
EP3600349A1 (en) 2020-02-05
US20200368276A1 (en) 2020-11-26
US20200390809A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CN114569633B (zh) 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
ES2859758T3 (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intestinal
JP6884889B2 (ja) 細菌株を含む組成物
EP3979830A1 (en) Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
JP6554468B6 (ja) ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するための医薬組成物
CN115003318A (zh) 包含细菌菌株的组合物
TW202116333A (zh) 包含細菌品系之組成物
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP2001158743A (ja) 乳酸菌含有組成物、医薬及び食品
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
JP2006176450A (ja) 小腸でのリンの過剰吸収を抑制可能とする乳酸菌含有組成物
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
JP2024525025A (ja) 不飽和ヒドロキサム酸誘導体及びアンモニア関連疾患若しくは障害の治療及び予防のためのそれらの使用
HK40071153A (en) Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
HK40071153B (en) Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
He et al. W2006 Beneficial Effects of Fermented Milk Containing Lactobacillus GG and L. Gasseri Tmc0356 On Regulating Intestinal Microflora and Immune Responses for Patients with Allergic Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Axial therapy Co.

Address before: Massachusetts, USA

Applicant before: Axial biotherapy Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220304